Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$153.2M
Filings
881
Firms Hired
13
Active Period
1999–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 3269, ETHIC Act, Biopharmaceutical patent and intellectual property policy issues
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3269
Joint Reserve Detachment (JRD) Formalization Act
2026 · third_quarter · Firm: YC CONSULTING, LLC
H.R. 3599, SECURE 340B Act, Issues related to drug pricing and patient access
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3599
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Consolidated Appropriations Act, 2026
2026 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Drug Competition Enhancement Act
2026 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Issues related to public health preparedness. Issues related to access to drugs for minority communities. Issues related to healthcare education and screening. Issues related to 340B Reform; H.R.9599, SECURE 340B Act. Issues related to PBM Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R.9599
H.R. 3269, ETHIC Act, Biopharmaceutical patent and intellectual property policy issues
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3269
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Consolidated Appropriations Act, 2026
2026 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Drug Competition Enhancement Act
2026 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
H.R. 3269, ETHIC Act, Biopharmaceutical patent and intellectual property policy issues
Client expense: — · Firm income: $50,000
Matched citations: H.R. 3269
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2026 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Consolidated Appropriations Act, 2026
2026 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R.7148
Drug Competition Enhancement Act
2026 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2026 · first_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
Drug Competition Enhancement Act
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1040
Affordable Prescriptions for Patients Act
2025 · fourth_quarter · Firm: MARSHALL & POPP, LLC
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Client expense: — · Firm income: $60,000
Matched citations: S.1041
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Client expense: — · Firm income: $60,000
Matched citations: H.Con.Res. 14
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
2025 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1492
An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · third_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Client expense: — · Firm income: $60,000
Matched citations: S.Con.Res. 7
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.
Client expense: — · Firm income: $60,000
Matched citations: H.Con.Res. 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034.
2025 · second_quarter · Firm: MARSHALL & POPP, LLC
Issues related to budget reconciliation, including H.Con.Res. 14.
Client expense: — · Firm income: $60,000
Matched citations: H.Con.Res. 14
Source: Senate LDA